Arrowstreet Capital
LEGN icon

Arrowstreet Capital’s Legend Biotech LEGN Stock Holding History

Arrowstreet Capital’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.9M Buy
759,994
+353,093
+87% +$9.52M 0.01% 830
2026
Q1 		$7.36M Buy
406,901
+315,176
+344% +$6.01M ﹤0.01% 1032
2025
Q4 		$1.99M Buy
+91,725
New +$2.63M ﹤0.01% 1411
2024
Q2 		– Sell
-4,827
Closed -$271K – 1661
2024
Q1 		$271K Buy
+4,827
New +$291K ﹤0.01% 1540
2023
Q1 		– Sell
-5,903
Closed -$295K – 1440
2022
Q4 		$295K Sell
5,903
-140,184
-96% -$6.79M ﹤0.01% 1206
2022
Q3 		$5.96M Buy
+146,087
New +$6.86M 0.01% 619
2022
Q2 		– Sell
-48,365
Closed -$1.76M – 1337
2022
Q1 		$1.76M Buy
+48,365
New +$1.91M ﹤0.01% 832
2021
Q1 		– Sell
-8,279
Closed -$233K – 2390
2020
Q4 		$233K Buy
+8,279
New +$238K ﹤0.01% 2169

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Arrowstreet Capital's LEGN Position: Q2 2026 in Review

Arrowstreet Capital increased its Legend Biotech (LEGN) stake by 87% in Q2 2026, buying an estimated $9.52M and bringing the position to 759,994 shares worth $21.9M. The position accounts for 0.01% of the portfolio, ranked #830.

Arrowstreet Capital first reported a position in LEGN in Q4 2020 and has held it in 8 quarters since. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Arrowstreet Capital held 759,994 shares of Legend Biotech worth $21.9M as of Q2 2026.
  • Arrowstreet Capital bought 353,093 Legend Biotech shares in Q2 2026, an estimated $9.52M.
  • Legend Biotech made up 0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #830 holding.
  • Arrowstreet Capital first reported a position in Legend Biotech in Q4 2020 and has held it in 8 quarters since.
  • 219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.